CA2281430A1 - Compositions pour le soin de la peau et leur utilisation pour guerir la peau endommagee - Google Patents

Compositions pour le soin de la peau et leur utilisation pour guerir la peau endommagee Download PDF

Info

Publication number: CA2281430A1
Authority: CA; Canada
Prior art keywords: skin; skin care; phytosphingosine; care composition; cholesterol
Prior art date: 1999-06-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002281430A

Other languages

English (en)

Inventor

Hyun Joon Kim

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

INTERCOSM BIOTECH LABORATORIES Inc

Original Assignee

INTERCOSM BIOTECH LABORATORIES INC.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-03

Filing date

1999-09-03

Publication date

2000-12-03

1999-09-03 Application filed by INTERCOSM BIOTECH LABORATORIES INC. filed Critical INTERCOSM BIOTECH LABORATORIES INC.

2000-12-03 Publication of CA2281430A1 publication Critical patent/CA2281430A1/fr

Status Abandoned legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims abstract description 86
230000035876 healing Effects 0.000 title claims abstract description 13
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 43
AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 claims abstract description 36
AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 claims abstract description 36
229940033329 phytosphingosine Drugs 0.000 claims abstract description 36
229940106189 ceramide Drugs 0.000 claims abstract description 32
235000012000 cholesterol Nutrition 0.000 claims abstract description 21
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 12
235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 12
239000000194 fatty acid Substances 0.000 claims abstract description 12
229930195729 fatty acid Natural products 0.000 claims abstract description 12
150000004665 fatty acids Chemical class 0.000 claims abstract description 12
235000010445 lecithin Nutrition 0.000 claims abstract description 12
239000000787 lecithin Substances 0.000 claims abstract description 12
229940067606 lecithin Drugs 0.000 claims abstract description 12
206010000496 acne Diseases 0.000 claims abstract description 7
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 7
208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 6
YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 10
CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 10
SGTYQWGEVAMVKB-NXCFDTQHSA-N [(2s,3s,4r)-2-acetamido-3,4-diacetyloxyoctadecyl] acetate Chemical compound CCCCCCCCCCCCCC[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](NC(C)=O)COC(C)=O SGTYQWGEVAMVKB-NXCFDTQHSA-N 0.000 claims description 10
ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 10
VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 10
150000003839 salts Chemical class 0.000 claims description 7
235000021122 unsaturated fatty acids Nutrition 0.000 claims description 5
150000004670 unsaturated fatty acids Chemical class 0.000 claims description 5
125000003277 amino group Chemical group 0.000 claims description 4
125000004432 carbon atom Chemical group C* 0.000 claims description 4
OTKJDMGTUTTYMP-ZWKOTPCHSA-N sphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ZWKOTPCHSA-N 0.000 claims description 4
WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 claims description 3
OTKJDMGTUTTYMP-UHFFFAOYSA-N dihydrosphingosine Natural products CCCCCCCCCCCCCCCC(O)C(N)CO OTKJDMGTUTTYMP-UHFFFAOYSA-N 0.000 claims description 3
150000003038 phytosphingosines Chemical class 0.000 claims description 3
WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 claims description 2
150000001408 amides Chemical class 0.000 claims description 2
WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 claims description 2
206010061218 Inflammation Diseases 0.000 claims 1
230000004054 inflammatory process Effects 0.000 claims 1
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 1
210000003491 skin Anatomy 0.000 abstract description 88
239000012528 membrane Substances 0.000 abstract description 33
150000002632 lipids Chemical class 0.000 abstract description 28
210000000434 stratum corneum Anatomy 0.000 abstract description 23
150000001783 ceramides Chemical class 0.000 abstract description 22
230000000694 effects Effects 0.000 abstract description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 13
239000000470 constituent Substances 0.000 abstract description 12
230000001225 therapeutic effect Effects 0.000 abstract description 10
210000002615 epidermis Anatomy 0.000 abstract description 6
230000035515 penetration Effects 0.000 abstract description 6
238000012377 drug delivery Methods 0.000 abstract description 5
230000037365 barrier function of the epidermis Effects 0.000 abstract description 4
230000036571 hydration Effects 0.000 abstract description 4
238000006703 hydration reaction Methods 0.000 abstract description 4
230000002209 hydrophobic effect Effects 0.000 abstract description 4
206010016807 Fluid retention Diseases 0.000 abstract description 3
239000004480 active ingredient Substances 0.000 abstract description 3
239000013543 active substance Substances 0.000 abstract description 2
230000009467 reduction Effects 0.000 abstract description 2
238000012360 testing method Methods 0.000 description 14
241000700159 Rattus Species 0.000 description 11
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
239000000243 solution Substances 0.000 description 10
230000002500 effect on skin Effects 0.000 description 8
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
239000000047 product Substances 0.000 description 8
210000004927 skin cell Anatomy 0.000 description 8
208000027418 Wounds and injury Diseases 0.000 description 7
239000008346 aqueous phase Substances 0.000 description 7
208000014674 injury Diseases 0.000 description 7
239000012071 phase Substances 0.000 description 7
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
238000003756 stirring Methods 0.000 description 6
239000010410 layer Substances 0.000 description 5
238000005259 measurement Methods 0.000 description 5
238000000034 method Methods 0.000 description 5
239000002244 precipitate Substances 0.000 description 5
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
230000001580 bacterial effect Effects 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
238000002425 crystallisation Methods 0.000 description 4
230000008025 crystallization Effects 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
238000004090 dissolution Methods 0.000 description 4
238000009472 formulation Methods 0.000 description 4
239000004310 lactic acid Substances 0.000 description 4
235000014655 lactic acid Nutrition 0.000 description 4
239000007788 liquid Substances 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
150000007524 organic acids Chemical class 0.000 description 4
235000005985 organic acids Nutrition 0.000 description 4
150000003904 phospholipids Chemical class 0.000 description 4
238000011160 research Methods 0.000 description 4
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
150000004671 saturated fatty acids Chemical class 0.000 description 4
150000003410 sphingosines Chemical class 0.000 description 4
239000000126 substance Substances 0.000 description 4
230000036572 transepidermal water loss Effects 0.000 description 4
230000008733 trauma Effects 0.000 description 4
241000894006 Bacteria Species 0.000 description 3
BHYOQNUELFTYRT-UHFFFAOYSA-N Cholesterol sulfate Natural products C1C=C2CC(OS(O)(=O)=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 BHYOQNUELFTYRT-UHFFFAOYSA-N 0.000 description 3
235000021355 Stearic acid Nutrition 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
230000002159 abnormal effect Effects 0.000 description 3
230000000845 anti-microbial effect Effects 0.000 description 3
BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
230000006870 function Effects 0.000 description 3
239000000463 material Substances 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
230000003020 moisturizing effect Effects 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
239000003883 ointment base Substances 0.000 description 3
239000002243 precursor Substances 0.000 description 3
208000017520 skin disease Diseases 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000008117 stearic acid Substances 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
208000019300 CLIPPERS Diseases 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
241000446313 Lamella Species 0.000 description 2
239000004909 Moisturizer Substances 0.000 description 2
239000005642 Oleic acid Substances 0.000 description 2
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 2
239000002537 cosmetic Substances 0.000 description 2
238000004945 emulsification Methods 0.000 description 2
210000004209 hair Anatomy 0.000 description 2
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
229910000041 hydrogen chloride Inorganic materials 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
230000003902 lesion Effects 0.000 description 2
239000002502 liposome Substances 0.000 description 2
239000004973 liquid crystal related substance Substances 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
244000005706 microflora Species 0.000 description 2
230000001333 moisturizer Effects 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
239000002674 ointment Substances 0.000 description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
239000003961 penetration enhancing agent Substances 0.000 description 2
229960004889 salicylic acid Drugs 0.000 description 2
235000003441 saturated fatty acids Nutrition 0.000 description 2
241000894007 species Species 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
150000003626 triacylglycerols Chemical class 0.000 description 2
RMXDHEVVOFNITF-ZCNNSNEGSA-N (15R,16S,17S)-17-amino-15,16,18-trihydroxyoctadecane-1,1,1-tricarbaldehyde Chemical compound C(=O)C(CCCCCCCCCCCCC[C@H]([C@H]([C@H](CO)N)O)O)(C=O)C=O RMXDHEVVOFNITF-ZCNNSNEGSA-N 0.000 description 1
GDKAAHDFPOWGQE-RXQQAGQTSA-N (2s,3s,4r)-2-aminooctadecane-1,3,4-triol;hydrochloride Chemical compound Cl.CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO GDKAAHDFPOWGQE-RXQQAGQTSA-N 0.000 description 1
OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
239000000232 Lipid Bilayer Substances 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
206010048222 Xerosis Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000011149 active material Substances 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
230000003260 anti-sepsis Effects 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000008827 biological function Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
125000001549 ceramide group Chemical group 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
150000001841 cholesterols Chemical class 0.000 description 1
239000013078 crystal Substances 0.000 description 1
210000004207 dermis Anatomy 0.000 description 1
238000011161 development Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
235000021588 free fatty acids Nutrition 0.000 description 1
230000036541 health Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
210000002510 keratinocyte Anatomy 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
238000005457 optimization Methods 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000008439 repair process Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000008591 skin barrier function Effects 0.000 description 1
230000036620 skin dryness Effects 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
150000003408 sphingolipids Chemical class 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229940086542 triethylamine Drugs 0.000 description 1
239000003981 vehicle Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Birds (AREA)
Dermatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Emergency Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Cosmetics (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA002281430A 1999-06-03 1999-09-03 Compositions pour le soin de la peau et leur utilisation pour guerir la peau endommagee Abandoned CA2281430A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
KR1019990026753A KR19990078610A (ko)	1999-07-03	1999-07-03	피부보호용조성물
KR1999-26753		1999-07-03

Publications (1)

Publication Number	Publication Date
CA2281430A1 true CA2281430A1 (fr)	2000-12-03

Family

ID=19599212

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002281430A Abandoned CA2281430A1 (fr)	1999-06-03	1999-09-03	Compositions pour le soin de la peau et leur utilisation pour guerir la peau endommagee

Country Status (5)

Country	Link
JP (1)	JP2001039859A (fr)
KR (1)	KR19990078610A (fr)
CA (1)	CA2281430A1 (fr)
FR (1)	FR2794366A1 (fr)
IT (1)	IT1314186B1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN100340227C (zh) *	2001-12-10	2007-10-03	花王株式会社	神经酰胺类乳化物
US8029810B2 (en)	2002-03-13	2011-10-04	Thomas Skold	Water-based delivery systems
US8178584B2 (en) *	2003-06-10	2012-05-15	Kao Corporation	Water-in oil emulsified composition
US10406088B2 (en)	2015-01-20	2019-09-10	TetraDerm Group LLC	Versatile topical drug delivery vehicle and multifactorial tissue moisturizer that provides mucosal and skin barrier restoration

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100396476B1 (ko) *	1999-07-30	2003-09-02	주식회사 참 존	화장품용 크림 조성물
FR2820037B1 (fr) *	2001-01-29	2005-12-09	Dermaconcept Jmc	Composition dermatologique a usage veterinaire comprenant une base sphingoide
FR2820038B1 (fr) *	2001-01-29	2004-07-02	Dermaconcept Jmc	Composition dermatologique a usage veterinaire comprenant une base sphingoide
KR100404072B1 (ko) *	2001-03-12	2003-11-03	주식회사 두산	광범위 피부질환 치료용 조성물
KR20010044801A (ko) *	2001-03-26	2001-06-05	최승철	엔-아세틸파이토스핑고신의 레틴아미드 유도체 및 그의제조방법
KR100429404B1 (ko) *	2001-03-31	2004-04-29	엔프라니 주식회사	저자극성 및 고보습형 화장료 조성물
SE0102087D0 (sv) *	2001-06-13	2001-06-13	Knut Haadem Med Haadem Invest	Skin preparation
CN1827766B (zh) *	2001-06-28	2010-08-25	徐荣祥	体外细胞的培养方法
CH695085A5 (de)	2001-07-13	2005-12-15	Mibelle Ag Cosmetics	Formulierungen zur Pflege der Haut nach Laserbehandlungen und/oder chemischen Peelings und Verwendung der Formulierungen.
KR100423102B1 (ko) *	2001-08-13	2004-03-16	주식회사 참 존	항암활성을 가지는 파이토스핑고신 유도체
KR100867679B1 (ko) *	2001-08-14	2008-11-10	주식회사 참 존	천연 액정조성물 및 이를 포함하는 화장료 조성물
DE60117900D1 (de) *	2001-09-05	2006-05-11	Charmzone Co	Phytosphingosinderivate mit Antitumorwirkung
US6538032B1 (en)	2001-09-07	2003-03-25	Charmzone Co., Ltd.	Phytosphingosine derivatives with antitumor activity
KR20030068698A (ko) *	2002-02-16	2003-08-25	한국화장품주식회사	미세다중 라멜라 소구체를 함유하는 미백 화장료 조성물및 그 제조 방법
WO2003092667A1 (fr) *	2002-05-02	2003-11-13	Doosan Corporation	Composition permettant de traiter le cancer comprenant n,n-dimethylphytosphingosine
KR100452757B1 (ko) *	2002-05-02	2004-10-12	앨트웰코스메틱 주식회사	천연세라마이드, 파이토스핑고신, 콜레스테롤 및 레시틴을 함유하는 피부보호용 조성물의 제조방법
WO2004016257A1 (fr) *	2002-08-14	2004-02-26	Tae-Yoon Kim	Composition comprenant des derives de phytosphingosine utiles dans l'induction de l'apoptose
FR2853835B1 (fr) *	2003-04-15	2008-07-04	Fabre Pierre Dermo Cosmetique	Extrait de pulpe de fruit pauvre en lipides
CH693624A5 (it) *	2003-05-22	2003-11-28	Gecomwert Anstalt	Preparati per la protezione solare, abbronzanti e di trattamento della pelle esposta al sole, atti ad aumentare e prolungare l'abbronzatura.
WO2005044217A1 (fr) *	2003-11-11	2005-05-19	Doosan Corporation	Procede de preparation d'une composition de liposomes de phytosphingosine
JP2006028109A (ja) *	2004-07-20	2006-02-02	Kao Corp	水中油型乳化組成物
TWI361698B (en)	2005-06-14	2012-04-11	Asahi Kasei Chemicals Corp	Composition for protecting human body surface
JP4954531B2 (ja) *	2005-10-31	2012-06-20	一丸ファルコス株式会社	ペルオキシソーム増殖剤応答性受容体活性化剤
JP5465871B2 (ja) *	2008-12-12	2014-04-09	花王株式会社	ニキビ改善剤
CN103445975B (zh) *	2012-05-30	2017-08-22	花王株式会社	乳化化妆品组合物
EP2829303A1 (fr) *	2013-07-22	2015-01-28	Johnson & Johnson Consumer Companies Inc.	Compositions comprenant un extrait de neglecta de malva et procédé de traitement d'une affection cutanée avec du neglecta de malva
KR101687573B1 (ko)	2013-08-28	2016-12-19	주식회사 엘씨에스바이오텍	피부지질 복합체

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR930007433A (ko) *	1991-10-19	1993-05-20	최근선	화장료용 안료 및 그 제조방법
KR960009644B1 (ko) *	1993-03-31	1996-07-23	임충헌	피부활성 미용성분을 함유한 미세다중 소구체(Micro Multiple Sphere)조성물 및 그 제조방법
KR0159184B1 (ko) *	1995-02-04	1998-12-01	문홍석	양모제 조성물 및 그 제조방법
JP3400666B2 (ja) *	1996-12-20	2003-04-28	高砂香料工業株式会社	皮膚保護剤
US6063387A (en) *	1997-04-17	2000-05-16	Elizabeth Arden Co., Division Of Conopco, Inc.	Anhydrous cosmetic composition with ceramides for firming skin
DE69912254T2 (de) *	1998-03-16	2004-08-26	Unilever N.V.	Kosmetisches verfahren zur hautbehandlung

1999
- 1999-07-03 KR KR1019990026753A patent/KR19990078610A/ko not_active Ceased
- 1999-09-03 FR FR9911061A patent/FR2794366A1/fr not_active Withdrawn
- 1999-09-03 JP JP11250846A patent/JP2001039859A/ja active Pending
- 1999-09-03 CA CA002281430A patent/CA2281430A1/fr not_active Abandoned
- 1999-09-08 IT IT99MI001884 patent/IT1314186B1/it active

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN100340227C (zh) *	2001-12-10	2007-10-03	花王株式会社	神经酰胺类乳化物
US7846969B2 (en)	2001-12-10	2010-12-07	Kao Corporation	Ceramide emulsions
US8029810B2 (en)	2002-03-13	2011-10-04	Thomas Skold	Water-based delivery systems
US8178584B2 (en) *	2003-06-10	2012-05-15	Kao Corporation	Water-in oil emulsified composition
US10406088B2 (en)	2015-01-20	2019-09-10	TetraDerm Group LLC	Versatile topical drug delivery vehicle and multifactorial tissue moisturizer that provides mucosal and skin barrier restoration

Also Published As

Publication number	Publication date
IT1314186B1 (it)	2002-12-06
FR2794366A1 (fr)	2000-12-08
ITMI991884A1 (it)	2001-03-08
KR19990078610A (ko)	1999-11-05
ITMI991884A0 (it)	1999-09-08
JP2001039859A (ja)	2001-02-13

Legal Events

Date	Code	Title	Description
2003-09-03	FZDE	Discontinued

Publication	Publication Date	Title
KR19990078610A (ko)	1999-11-05	피부보호용조성물
CN114177109B (zh)	2023-01-17	一种复合神经酰胺纳米组合物及其制备方法和应用
US6964952B2 (en)	2005-11-15	Therapeutic composition for broad spectrum dermal disease
US5147859A (en)	1992-09-15	Complexes of glycerrhetinic acid with phospholipids and pharmaceutical and cosmetic compositions containing them
RU2121340C1 (ru)	1998-11-10	Состав для похудения для местного применения, содержащий два типа липосом, и способ уменьшения и/или устранения полноты и/или избыточного веса
US9849079B2 (en)	2017-12-26	Medicinal skin protection composition with an active ingredient combination which improves the skin barrier
KR100371491B1 (ko)	2003-02-07	피부 보호용 크림조성물
JP2001510487A (ja)	2001-07-31	遊離スフィンゴイド塩基及びセラミドの組合せを含む組成物並びにその使用
WO1997016166A1 (fr)	1997-05-09	Composition de soin de beaute et procede correspondant
WO2001017523A1 (fr)	2001-03-15	Compositions et methodes pour modifier le taux de lipides cutanes
KR20050026778A (ko)	2005-03-16	세포간 지질 성분의 나노리포좀을 함유하는 피부자극완화용 화장료 조성물
CA1329364C (fr)	1994-05-10	Compositions cosmetiques ayant des proprietes therapeutiques
JP3884581B2 (ja)	2007-02-21	ニキビ予防・改善剤
KR101461625B1 (ko)	2014-11-20	16-히드록시헥사데카노익 피토스핑고신을 유효성분으로 포함하는 피부장벽 손상의 개선 또는 치료, 또는 피부장벽 기능의 개선 또는 강화용 조성물
US6372236B1 (en)	2002-04-16	Cream composition for skin care
KR100343885B1 (ko)	2002-07-19	파이토스핑고신의 수용액의 제조 방법
KR102503769B1 (ko)	2023-02-27	측쇄 지방산을 포함하는 신규한 스핑고지질과 그의 용도
JP2021038178A (ja)	2021-03-11	ベシクル組成物、それを含有する化粧料及び皮膚外用剤
KR101598210B1 (ko)	2016-03-03	보습 펩타이드, 세라마이드를 함유하는 투명한 젤상 가용화 조성물
JP2022092861A (ja)	2022-06-23	セラミド含有リポソーム
KR20000018910A (ko)	2000-04-06	여드름 피부용 조성물
JP4246150B2 (ja)	2009-04-02	皮膚化粧料組成物
KR20030015425A (ko)	2003-02-25	천연 액정조성물 및 이를 포함하는 화장료 조성물
SUMMERLY et al.	1972	The effect of eicosa 5: 8: 11: 14 tetraynoic acid on skin lipid synthesis (14C incorporation) in vitro
WO2018123002A1 (fr)	2018-07-05	Composition pour application externe